Article Data

  • Views 431
  • Dowloads 140

Original Research

Open Access

Assessment of primary radical hysterectomy and neoadjuvant chemotherapy followed by radical hysterectomy in Stage IB2, IIA bulky cervical cancer

  • A. Musaev1
  • A.B. Guzel1
  • G. Khatib1,*,
  • U.K. Gulec1
  • M.A. Vardar1
  • A. Altıntas1
  • D. Gumurdulu2

1Department of Obstetrics and Gynecology, Faculty of Medicine, Cukurova University, Adana, Turkey

2Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey

DOI: 10.12892/ejgo2629.2015 Vol.36,Issue 5,October 2015 pp.579-584

Published: 10 October 2015

*Corresponding Author(s): G. Khatib E-mail: ghanim.khatib@gmail.com

Abstract

Objective: Uncertainty concerning the treatment of Stage IB2-IIA (bulky) cervical cancer is still continuing. In this study, an analysis of Stage IB2-IIA (bulky) cervical cancer was performed. The efficacy of primary radical surgery and neoadjuvant chemotherapy followed by a radical surgery was investigated. Materials and Methods: Medical data of 50 patients who were diagnosed with Stage IB2-IIA (bulky) cervical cancer and treated between 2002-2009 were retrospectively assessed. In the radical surgery group, radical hysterectomy + bilateral pelvic + para-aortic lymphadenectomy were performed. In the neoadjuvant chemotherapy group, a combination of cisplatin/topotecan or paclitaxel/carboplatin was given to the patients and then radical surgery was performed. Each group was evaluated individually. Prognostic factors were determined and survival rates were compared between the groups. A p value was taken < 0.05 for the statistical significance level for all results. Results: Radical surgery after neoadjuvant chemotherapy was performed in 21 and primary radical surgery in 29 patients. Median follow-up time was 36.0 ± 14.0 months. Average of the tumor size before treatment was 50.2 ± 7.6 mm. In the radical surgery after neoadjuvant chemotherapy group, lymphovascular space invasion (LVSI) and tumor size (before and after treatment) were determined to be significant factors for each of disease-free survival (DFS) and overall survival (OS). On multivariate analysis, tumor size (before treatment) was found to be an independent prognostic factor for both of DFS (p = 0.006) and OS (p = 0.010). No significant difference in survival periods was observed among the groups. Conclusion: There was no significant superiority among the two treatment options. Nonetheless, further studies are needed to compare the multimodal approaches in these stages of cervical cancer.

Keywords

Stage IB2-IIA (bulky) cervical cancer; Neoadjuvant chemotherapy; Radical hysterectomy.

Cite and Share

A. Musaev,A.B. Guzel,G. Khatib,U.K. Gulec,M.A. Vardar,A. Altıntas,D. Gumurdulu. Assessment of primary radical hysterectomy and neoadjuvant chemotherapy followed by radical hysterectomy in Stage IB2, IIA bulky cervical cancer. European Journal of Gynaecological Oncology. 2015. 36(5);579-584.

References

[1] Quinn M.A., Benedet J.L., Odicino F., Maisonneuve P., Beller U.: “Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Re-sults of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Ob-stet., 2006, 95, 43.

[2] Gong L., Lou J.Y., Wang P., Zhang J.W., Liu H., Peng Z.L.: “Clini-cal evaluation of neoadjuvant chemotherapy followed by radical surg ery in themanagement of stage IB2-IIB cervical cancer”. Int. J. Gy-naecol. Obstet., 2012, 117, 23.

[3] González-Martín A., Gonzalez-Cortijo L., Carballo N., Garcia J.F., Lapuente F.: “The current role of neoadjuvant chemotherapy in the management of cervical carcinoma”. Gynecol. Oncol., 2008, 110, 36.

[4] Kim H.S., Sardi J.E., Katsumata N., Ryu H.S., Nam J.H., Chung H. H., et al.: “Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: An international collaborative meta-analysis”. Eur. J. Surg. Oncol., 2013, 39, 115.

[5] Volterrani F., Feltre L., Sigurata D.: “Radyotherapy versus surgery in the treatment of cervix stage IB cancer”. Int. J. Radiat. Oncol. Biol. Phys., 1983, 91, 781.

[6] Serur E., Mathews R.P., Gates J., Levine P., Maiman M., Remy J.C.: “Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix”. Gynecol. Oncol., 1997, 94, 65, 348.

[7] Yessaian A., Magistris A., Burger A.B., Monk B.J.: “Radical hys-terectomy followed by tailored postoperative therapy in the treat-ment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy”. Gynecol. Oncol., 2004, 94, 61.

[8] Finan M.A., DeCesare S., Fiorica J.V.: “Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging sys-tem predict morbidity and survival?” Gynecol. Oncol., 1996, 62, 139.

[9] Landoni F., Maneo A., Colombo A.: “Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer”. Lancet, 1997, 350, 535.

[10] Aoki Y., Sato T., Watanabe M., Sasaki M., Tsuneki I., Tanaka K.: “Neoadjuvant chemotherapy using low-dose consecutive intraarter-ial infusions of cisplatin combined with 5-fluorouracil for locally ad-vanced cervical adenocarcinoma”. Gynecol. Oncol., 2001, 81, 496.

[11] Fuso L., Mazzola S., Marocco F.: “Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemother-apy in patients with locally advanced squamous cervical carcinoma: A preliminary report”. Gynecol. Oncol., 2005, 99, 187.

[12] Sardi J., Sananes C., Giaroli A.: “Results of a prospective trial with neoadjuvant chemotherapy in stage IB bulky, squamous carcinoma of the cerviks”. Gynecol. Oncol., 1993, 49, 156.

[13] Sardi J.E., Giaroli A., Sananes C.: “Long-term follow-up of the fisrt ran-domized trial using neoadjuvant chemoterapy in stage IB squamous car-cinoma of the cervix: the final results”. Gynecol. Oncol., 1997, 67, 61.

[14] Eddy G.L., Bundy B.N., Creasman W.T.: “Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterektomy and pelvic/para-aortic lym-phadenektomy: A phase III trial of the Gynecologic Oncology Group”. Gynecol. Oncol., 2007, 106, 362.

[15] Behtash N., Nazari Z., Ayatollahi H.: “Neoadjuvant chemotherapy and radical surgery compared to radikal surgery alane in bulky stage IB-IIA cervical cancer”. EJSO, 2006, 32, 1226.

[16] Fujiwaki R., Iida K., Ohnishi Y.: “Intra-arterial neoadjuvant chemotherapy followed by radical surgery and radiotherapy for stage IIB cervical carcinoma”. AntiCancer Res., 1997, 17, 3751.

[17] D’Agostino G., Distefano M., Greggi S.: “Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, pa-clitaxel and cisplatin”. Cancer Chemother. Pharmacol., 2002, 49, 256.

[18] Bonomi P., Blessing J.A., Stehman F.B.: “A randomized trial of three Cisplatinum dose schedules in squamous cell carcinoma of the uter-ine cerviks”. J. Clin. Oncol., 1985, 3, 1079.

[19] Buda A., Fossati R., Colombo N.: “Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide and cisplatin with ifosfamide and cisplatin fallowed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Srudy”. J. Clin. Oncol., 2005, 23, 4137.

[20] Park D.C., Kim J.H., Lew Y.O., Kim D.H., Namkoong S.E.: “Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical can-cer”. Gynecol. Oncol., 2004, 92, 59.

[21] Bermúdez A., Vighi S., García A., Sardi J. Neuroendocrine Cervical carcinoma; a diagnostic and therapeutic challenge”. Gynecol. Oncol., 2001, 82, 32.

[22] Kumar L., Crover R., Pokharel Y.H.: “Neoadjuvant chemotherapy in locally advenced cervical cancer: two randomised studies”. Aus. N. Z. J. Med., 1998, 28, 387.

[23] Choi Y.S., Sin J.I., Kim J.H., Ye G.W., Shin I.H., Lee T.S.: “Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical can-cer”. J. Korean Med. Sci., 2006, 21, 683.

[24] Huang H.J., Chang T.C., Hong J.H.: “Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky (≥4 cm) stage IB and IIA cervical carcinoma”. Int. J. Gynecol. Cancer, 2003, 13, 204.

[25] Bloss J.D., Lucci J.A., DiSaia P.J.: “A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix”. Gynecol. Oncol., 1995, 59, 105.

[26] Sananes C., Giaroli A., Soderini A.: “Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvant chemotherapy in the treatment of carcinoma of the cervix: Long-term follow-up a pilot study”. Eur. J. Gyneacol. Oncol., 1998, 19, 368.

[27] Namkoong S.E., Park J.S., Kim J.W.: “Comparative study of the pa-tients with locally advanced stages I and II cervical cancer treated by radical hysterectomy with or without preoperative adjuvant chemotherapy”. Gynecol. Oncol., 1995, 59, 136.

[28] Tabata T., Takeshima N., Nishida H., Hirai Y., Hasumi K.: “A ran-domized study of primary bleomycin, vincristine, mitomycin and cisplatin (BOMP) chemotherapy fallowed by radyotherapy versus radyotherapy alone in stage IIIB and IVA squamous cell carcinoma of the cervix”. AntiCancer Res., 2003, 23, 2885.

[29] Monoghan J.M., Ireland D., Shlomo M.Y., Pearson S.E., Lopes A., Sinha D.P.: “Role of centralization of surgery in stage IB carcinoma of the cervix: a review of 498 cases”. Gynecol. Oncol., 1990, 37, 206.

[30] Lai C.H., Hong J.H., Hsueh S., Ng K.K., Chang T.C., Tseng C.J., et al.: “Preoperative prognostic variables and the impact of postopera-tive adjuvant therapy on the outcomes of Stage IB or II cervical car-cinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases”. Cancer, 1999, 85, 1537.

[31] Samlal R.A.K., Van Der Velden J., Ten Kate F.J.W., Schilthuis M.S.: “Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes”. Cancer, 1997, 80, 1234.

[32] Kristensen G.B., Abeler V.M., Risberg B., Trope C., Bryne M.: “Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma”. Gynecol. Oncol., 1999, 74, 245.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top